Trades on 1 secondary market

Newleos Therapeutics

Newleos Therapeutics is a clinical-stage biotechnology company co-founded by Longwood Fund and seasoned CNS drug-development leaders, headquartered in Boston, Massachusetts. Its pipeline, licensed from Roche, develops oral small-molecule therapeutics targeting GABAA-gamma1, V1a, TAAR1 and GABAA-alph

minimal 12.3 / 100 0 APIs View provider profile →

Company Biotechnology Pharmaceuticals Mental Health Neuroscience Clinical Trials

Newleos Therapeutics is an API provider whose private shares are listed on 1 secondary market: Nasdaq Private Market.

Where It Trades

N Nasdaq Private Market View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.